Panelists discuss how treatment selection between combination immunotherapy (IO) and chemotherapy alone should favor the FDA-approved carboplatin-paclitaxel-retifanlimab regimen for most patients with ...

Panelists discuss how the PODIUM-303 study demonstrated improved progression-free survival (9.3 vs 7.4 months) and response rates (56% vs 44%) when adding retifanlimab to carboplatin-paclitaxel in ...

As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing ...

Analysts now project the global oncology drug market could surpass US$900 billion in revenue by 2034. Precedence Research ...

Cancer is a broad term used to describe the uncontrollable proliferation of mutated cells deleterious to the body. Any tissue in the body can become mutate | Immunology ...

A Ludwig Cancer Research study has identified a complex chain of molecular chatter by which cancer cells, exploiting ordinary ...

A specially engineered antibody that can accurately deliver RNA treatments into hard-to-reach and hard-to-treat tumors ...

Dr. Olalekan O. Oluwole explained how CAR T is used to treat high-risk blood cancers and highlighted the potential of ...

The Motley Fool. DATE Wednesday, July 16, 2025 at 8:30 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — ...